An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

Inclusion Criteria: * Participants must have a primary DSM-5 diagnosis of MDD * Must have a HDRS total score greater than or equal to (\>=) 18 at screening and predose at Day 1, as recorded by the remote independent rater and must not demonstrate an improvement of \> 25 percent (%) on their HDRS total score from the screening to baseline visit * Must be medically stable on the basis of physical examination, medical history, vital signs, clinical laboratory tests and 12-lead ECG performed at screening. If there are abnormalities, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the subject's source documents and initialed by the investigator * Participants with hypothyroidism who are on stable treatment for 3 months prior to screening are required to have thyroid stimulating hormone (TSH) and free thyroxine (FT4) obtained. If the TSH value is out of range, but FT4 is normal, such cases should be discussed directly with the medical monitor before the subject is enrolled. If the FT4 value is out of range, the participant is not eligible Exclusion Criteria: * Any other current Axis one psychiatric condition, including, but not limited to, MDD with current psychotic features, bipolar disorder (including lifetime diagnosis), obsessive-compulsive disorder, borderline personality disorder, eating disorder (eg, bulimia, anorexia nervosa), or schizophre…